Company News

PharmaJet and Abnova partner to develop and deliver COVID-19 mRNA Vaccine using Needle-free Injection technology

GOLDEN, Colo. — May 19, 2020 — PharmaJet^®, the maker of innovative, needle-free injection technology, today announced that its Needle-free Injection System technology will be used to deliver a messenger RNA (mRNA) vaccine against SARS-CoV-2. The vaccine is being developed by Abnova Corporation, the world’s largest antibody manufacturer, based in Taiwan.

Abnova has established a comprehensive portfolio of fully integrated solutions to address the needs for responding to SARS-CoV-2, including a novel adjuvant that can further increase the effectiveness of their mRNA candidate.

Details

PharmaJet Announces Executive Leadership Changes

GOLDEN, Colo. — April 28, 2020 — PharmaJet^®, the maker of innovative, needle-free injection technology, today announced the appointment of Chris Cappello to President and Chief Executive Officer. Chris replaces Ron Lowy, who was appointed Executive Chairman of the board.

Ron Lowy, Executive Chairman, PharmaJet Inc. said, “ In the 10 years that Chris has worked for PharmaJet he has shown the ability to lead the organization and expand on our important collaborations with groups such as the US federal government, the World Health Organization, multiple pharmaceutical partnerships…

Details

PharmaJet partners with Immunomic Therapeutics and EpiVax to develop and deliver COVID-19 Vaccine

GOLDEN, Colo. — April 14, 2020 — PharmaJet^®, the maker of innovative, needle-free injection technology, today announced that its Tropis^® Needle-free injection system will be used to deliver a COVID-19 vaccine being developed by Immunomic Therapeutics, Inc. (ITI). ITI is a clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms using the body’s natural biochemistry to generate a broad immune response. The vaccine candidate against COVID-19 will leverage their investigational UNiversal Intracellular Targeted Expression (UNITE^TM) platform. Details

Immunomic Therapeutics Forms Collaboration with EpiVax and PharmaJet to Develop Novel Vaccine Candidate Against COVID-19 Using its Investigational UNITE Platform

ROCKVILLE, MD, PROVIDENCE, RI, and GOLDEN, CO — April 09, 2020 — Immunomic Therapeutics, Inc., a privately held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced today that it is developing a nucleic acid vaccine candidate against COVID-19 leveraging its investigational UNITE platform for prevention of the novel coronavirus disease caused by SARS-Cov-2 coronavirus. Details

PharmaJet Announces Appointment of Pharmaceutical Executive Dr. Marie Mazur to the Board of Directors

GOLDEN, Colo. — March 25, 2020 — PharmaJet^®, the maker of innovative, needle-free injection technology, today announced that Dr. Marie Mazur, has been appointed to its Board of Directors. Dr. Mazur is a global business executive with over 30 years of experience growing revenue and profits for major vaccine and pharmaceutical companies.

Ron Lowy, Executive Chairman, PharmaJet Inc. said, “we are very pleased to welcome Dr. Mazur to the PharmaJet Board of Directors." Details

PharmaJet Received Multi-Year, Multi-Million Dollar Award to Support Next-Generation Needle-free Delivery Devices

GOLDEN, Colo. — March 17, 2020 — PharmaJet^®, the maker of innovative, needle-free injection technology, announced that it received a $9.6 million dollar contract award from the Joint Science and Technology Office of the U.S. Defense Threat Reduction Agency (DTRA). DTRA, through the Medical CBRN Defense Consortium (MCDC), is funding the use of needle-free technology to further progress promising nucleic acid vaccines, while also funding the development of PharmaJet’s next generation needle-free devices. Details

First large-scale polio vaccination campaign using PharmaJet intradermal Needle-free Injector

GOLDEN, Colo. — February 5, 2020 — PharmaJet^®, the maker of innovative, needle-free injection technology, today announced the publication of independent survey results from the first large-scale campaign using its needle-free technology. The paper, entitled Needle-free injectors for mass administration of fractional dose inactivated poliovirus vaccine (fIPV) in Karachi, Pakistan: A survey of caregiver and vaccinator acceptability, was published in Vaccine on January 23, 2020. Details

Phase I clinical trial results published for Invectys DNA Vaccine for Cancer using PharmaJet Needle-free injector

GOLDEN, Colo. — January 8, 2020 — PharmaJet^®, the maker of innovative, needle-free injection technology, announced that the results of the Invectys Phase I clinical trial of its therapeutic cancer vaccine, INVAC-1, using the PharmaJet needle-free injection system, were recently published. The study entitled A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid Tumors was published in Clinical Cancer Research on November 19, 2019. Details

PharmaJet Announces Appointment of Kevin L. Lorenz, J.D., to Board of Directors

GOLDEN, Colo. — December 17, 2019 — PharmaJet^®, the maker of innovative, needle-free injection technology, today announced that Kevin L. Lorenz, J.D., has been appointed to its Board of Directors. Mr. Lorenz, Chief Investment Officer, Senior Vice President, Treasury and Private Investments at the Katz Group, is an accomplished executive with over 25 years of experience guiding and implementing investment strategy across public and private companies. Details

PharmaJet presents latest Research Results at World Vaccine Congress

GOLDEN, Colo. — May 7, 2019 — PharmaJet^®, the maker of innovative, needle-free injection technology, today shared that their latest research results were presented at the World Vaccine Congress on April 16, in Washington DC at the Renaissance Washington DC Downtown Hotel. The presentation, entitled Expanding Vaccine Effective-ness with Needle-free Delivery, was presented by Dr. Marilyn Dysart, Clinical Affairs Manager at PharmaJet, Inc. Details